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ABSTRACT. 
Introduction. Asymptomatic patients with human immunodeficiency virus (HIV) 
infection are at increased risk of vascular disease. Whether asymptomatic HIV patients 
have increased prevalence or structural differences in coronary artery plaques is not clear. 
Methods. Pubmed, Cochrane and Google Scholar were searched for articles 
evaluating asymptomatic HIV patients evaluated with coronary computed tomography. The 
prevalence of coronary stenosis (defined as >30% and > 50%), of calcified coronary 
plaques (CCP) viewed as more ‘stable’ plaques, and of non-calcified coronary plaques 
(NCP) viewed as more ‘vulnerable’ plaques were the end points of interest. 
Results.   9 studies with 1229 HIV patients and 1029 controls were included. No 
significant differences were detected about baseline cardiovascular risk profile. The 
prevalence of significant coronary stenosis >30% or >50% did not differ between HIV+ and 
HIV- patients (42% [37-44] and 46% [35-52] with an Odds Ratio [OR] of 1.38 [0.86-2.20] 
for >30% stenosis) and (15% [9-21] and 14% [7-22] with an OR of 1.11 [0.81-1.52]), 
respectively. The prevalence of calcified coronary plaques (CCP) (31% [24-32] and 21% 
[14-30] with an OR of 1.17 [0.63-2.16]) also did not differ among HIV+ and HIV- patients. 
On the contrary rates of NCP were >3-fold higher in HIV-positive patients [58% (48-60) 
and 17% (14-27) with an OR of 3.26 (1-30-8.18)], with an inverse relationship with CD4 
cell count at meta-regression (Beta -0.20 [-0.35-0.18], p 0.04). 
Conclusion. Asymptomatic HIV patients present a similar burden of coronary 
stenosis and calcified coronary artery plaques but significantly higher rates of non-calcific 
coronary plaques at computed tomography. The association between HIV infection, 
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reduced CD4 cell counts and higher prevalence on non-calcific coronary artery plaques 
may shed light into the pathogenesis in HIV-associated coronary artery disease, stressing 
the importance of primary prevention in this population. 
 
INTRODUCTION. 
Life expectancy of human immunodeficiency virus (HIV) patients dramatically 
increased thanks to highly active antiretroviral therapy (HAART)1. Physicians managing 
these patients are shifting towards a more global assessment of clinical conditions, with a 
particular attention of development of both clinical and subclinical cardiovascular 
disease2,3. 
HIV patients, actually, are exposed for many years to the continuous interaction 
between traditional risk factors, coronary HIV infection, immune-mediated response and 
the still debated effect of HAART3,4. 
In acute coronary syndrome (ACS) settings, this peculiar pathological pattern has 
led to a higher risk of coronary adverse events; several challenges have been identified in 
those patients, such as drug to drug interaction with new antiaggregants or statins and 
compliance to medications4. 
 Consequently, primary care is becoming crucial, both to prevent subclinical 
impairment of systolic and diastolic dysfunction5 and to reduce number of cardiovascular 
adverse events3. Even subclinical atherosclerosis has been related with risk for 
cardiovascular events in the general population7,8, and particular for those presenting with 
non-calcified plaques due to a higher risk of rupture9.  An increased use of coronary  
computed tomography (CCT) has been reported, both to measure coronary artery calcium 
(CAC) and to evaluate the prevalence and features of coronary plaques, in order to 
accurately address pharmacological and interventional strategies10-12.  
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Some studies have found a higher prevalence of subclinical atherosclerosis in HIV-
positive patients13-15 but the results are not consistent. Consequently we performed a 
systematic review to understand the prevalence and the peculiarities of coronary plaques 
in asymptomatic HIV-positive patients. 
METHODS. 
The Cochrane Collaboration and Meta-analysis Of Observational Studies in 
Epidemiology (MOOSE)18 was followed during elaboration of the present analysis. 
 
Search strategy and study selection. 
Pertinent articles were searched in Medline, Cochrane Library, Biomed Central and 
Google Scholar in keeping with established methods16  with Mesh strategy: ((coronary 
computed tomography) OR (CCT)) AND (hiv OR aids OR (human AND immunodeficiency 
AND virus)).  
Two independent reviewers (F.DA, E.C.) first screened retrieved citations at the title 
and/or abstract level, with divergences resolved after consensus. If potentially pertinent, 
they were then appraised as complete reports according to the following explicit selection 
criteria. Studies were included if (i) investigating with CCT asymptomatic HIV and non HIV 
patients (ii) with more than 90% of patients treated with HAART. Exclusion criteria was (i) 
absence of non HIV controls. 
 
Data extraction 
Two unblinded independent reviewers (G.B.-Z, F.DA, and E.C.) abstracted the 
following data on pre-specified forms: authors, journal, year of publication, location of the 
study group, baseline features, type and timing of antiretroviral therapy, and protocols of 
CCT. The prevalence of coronary stenosis (more than 30% and more than 50%), of 
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calcified coronary (CCP), of non-calcified coronary plaques (NCP) and of Coronary Artery 
Calcification Score (CAC) more than 0 were the end points of interest. 
 
Internal validity and quality appraisal 
Unblinded independent reviewers (G.B.-Z, F.DA, and E.C.) evaluated quality of 
included studies on pre-specified forms. Modifying the MOOSE items to take into account 
the specific features of included studies,15-18 we separately abstracted and appraised study 
design, setting, data source, as well as risk of analytical, selection, adjudication, detection, 
and attrition bias (expressed as low, moderate, or high risk of bias, as well as incomplete 
reporting leading to inability to ascertain the underlying risk of bias). For  the  quality  
assessment  of  the  selected  studies  we  used  the  Newcastle-Ottawa  Scale (NOS) for 
Assessing the Quality of Nonrandomized Studies in Meta-Analysis19. 
 
Data analysis and synthesis 
Continuous variables are reported as mean (standard deviation) or median (range). 
Categorical variables are expressed as n/N (%). Statistical pooling was performed 
according to a random-effect model with generic inverse-variance weighting, computing 
risk estimates with 95% confidence intervals, using RevMan 5 (The Cochrane 
Collaboration, The Nordic Cochrane Centre, and Copenhagen, Denmark). Meta-
regression analysis for the impact of traditional risk factors and HIV features on the 
primary end point was performed with random effect with Comprehensive Meta-
Analysis after computation of the event rate. All confidence intervals were of 95%). 









217 studies were first screened at abstract level, and after evaluation 9 studies with 
1229 HIV patients and 1029 controls were included20-28. (see Figure 1). Eight studies out 
of nine were prospective: eight were performed in the USA and one in Europe. 
 Baseline features of the included patients are reported in Table 1. HIV 
patients were more frequently of male gender, with higher rates of diabetes mellitus and of 
hypertension in the included studies, but without significant differences. 
Concerning immunovirological variables these patients had been on HAART for 8.3 
(8-9) years, with a CD4+ T lymphocyte cell count of 529/mm3 (525-571) and a CD4+ nadir 
of 201 cells/mm3 (181-257). 52% (51-53) have been exposed to Protease Inhibitors (PI), 
94% (81-96) to nonnucleoside reverse-transcriptase inhibitors (NNRT) and 46% (43-47) to   
nucleoside reverse-transcriptase inhibitors (NRTIs). 
In all studies, included patients were asymptomatic and only in the study of 
D’Abramo et al20, they were included after a positive ergometric test. Protocols and 
definitions of CCT were consistent among all studies (Table A, Appendix web only). 
Prevalence of significant coronary stenosis (>30%) did not differ between HIV+ and 
HIV- patients [42% (37-44) and 46% (35-52) with an Odds Ratio (OR) of 1.38 (0.86-2.20)]. 
Similarly prevalence of coronary stenosis above 50% (15% 9-21 and 14% 7-22 with an OR 
of 1.11 [0.81-1.52]), of calcific coronary plaques (31% 24-32 and 21% 14-30 with an OR of 
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1.17 [0.63-2.16] and of CAC above zero (43% [39-48] and 46% [26-56] with an OR of 0.88 
[0.43-1,79] did not differ among HIV+ and HIV- patients (see Figures 2 and 3). On the 
contrary rates of NCP were significantly higher in HIV-positive patients [58% (48-60) and 
17% (14-27) with an OR of 3.26 (1-30-8.18)].  
At meta-regression analysis for coronary stenosis above 30% active smoking habit 
increased the risk (Beta 0.02 0.01-0.03, p<0.001) in HIV+, Immunologic status and HAART 
therapy showed a neutral effect. Moreover, CD4 cell counts was inversely related to the 
risk of non-calcific plaque (the higher CD4 cell counts the lower the prevalence, Beta -0.20 
-0.35-0.18 p 0.04). (see Tables 3 and 4, Figure 5). 
At funnel plot analysis, low selection bias was noted (Figure A). 
 
DISCUSSION 
This is the first paper reporting a pooled analysis of data about CCT scan in 
asymptomatic HIV patients. The main findings are: 1) HIV-infected patients present higher 
rates of NCP compared to similar cohorts of HIV-negative subjects 2) NCP prevalence and 
degree were positively associated with worse immunovirological parameters, suggesting 
that disease stage contributes to cardiovascular instability. 
NCP represent an early stage of atherosclerosis, resulting to be more prone to 
rupture and thrombus formation compared than calcified ones, potentially leading to ACS. 
These observations were already reported in series of patients evaluated by CCT as well 
in ACS patients undergoing angiography followed by grayscale and radiofrequency 
intravascular ultrasonography (IVUS)30,31 and were also consistent with pathological 
studies reporting that plaque more prone to rupture show a thin cap fibro atheroma and 
necrotic core with an overlying thin fibrous cap32,33.  
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Previous CCT studies reported a higher prevalence of NCP in intermediate-risk 
asymptomatic patients, especially in those with significantly higher level of C-reactive 
protein, cholesterol (total and low-density lipoprotein) as well as a trend for a higher 
prevalence of diabetes mellitus34. Our analysis includes a young population (median age 
of 47 years) with a low prevalence of diabetes and a moderate prevalence of 
hyperlipidemia (11% and 27% respectively). Despite these characteristics, the prevalence 
of NCP was 3-fold higher compared with similar Framingham-based score non-HIV 
population (58% vs. 17%) and comparable to the one reported in recent study35 by Park et 
al (NCP rate = 56%).  
We reported a CAC score value higher than zero in less than half of subjects. Even 
if CAC score of zero was associated with very low risk of cardiac events, NCP plaque 
cannot be detected on non-contrast cardiac scans, used to measure CAC levels. Previous 
studies utilizing CCT to estimate the extent of coronary artery disease in HIV 
patients assessed only CAC by scoring without explore directly the lumen caliber or 
plaques burden36,37. Although the CAC scoring is a well defined marker for 
atherosclerotic lesions and cardiac event risk in non-HIV population, it may not 
provide a reliable valuation of early atherosclerosis  in  young  HIV  patients in 
whom calcifications are absent: our finding demonstrate that a significant 
proportion of patients with coronary atherosclerosis may be missed using only 
calcium score criterion. Thus we stressed the additional value of adopting CCT over 
CAC scoring alone for the assessment of coronary tree in young HIV-positive 
patients; since CCP probably reflects advanced stable atherosclerosis while 
identifying NCP seem crucial in this group of patients. 
Additionally we reported a significant correlation between low CD4 cell counts and risk of 
NCP. The association between CD4 cell count and cardiovascular disease has already 
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been previously reported and it may be related to immune-dysfunction (immune activation 
and immune senescence) or to the prevalence of other infection potentially affecting 
endothelial cells (cytomegalovirus, HHV-8, and others)38-40. Similarly, previous studies 
reported a low CD4+ count to be associated with a high prevalence of carotid artery 
plaques41: our findings strengthen these observations supporting the hypothesis of 
a systemic inflammatory dysregulation in HIV-positive patients. 
The only other variable that showed a positive interaction on the risk of coronary 
stenosis was active smoking status, accordingly to the higher risk of smoker-related 
comorbidities previously reported in HIV-infected than uninfected patient. Notably, these 
subgroup are actually an attractive target for a “multi-disease” screening since that recent 
studies are currently investigating the role of CT for lung cancer prevention in HIV-positive 
smokers even if with sparse results42-44. 
Clinical implications of present study may be of interest for physicians, cardiologists, 
infective disease specialists and general practitioners. Plaque characteristics observed 
using CCT underline the vulnerable atherosclerotic pattern of HIV-positive subjects, 
suggesting the need of aggressive primary prevention programs in this specific 
population. These data highlight the importance of addressing modifiable 
cardiovascular risk factors to optimize long-term health in the setting of HIV 
infection comorbidities. Although not confirmed in randomized controlled trial, 
statins use may be crucial, for their effect on plaques stability. A parallel focus on 
smoking cessation is important, considering the interaction on the risk of coronary 
stenosis demonstrated from several studies. Furthermore several data report the 
underuse of aspirin in primary prevention45 in high-risk HIV-positive patients despite 
heightened awareness regarding elevated cardiovascular risk, although the absence 
of randomized controlled trials may explain such conduct. 
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Finally even if a CCT based approach for primary prevention has never been 
suggested to improve prognosis, these results may advise HIV physicians to 
evaluate and to focus on plaque characteristics in order to select appropriate 
primary prevention strategies. 
 
LIMITATIONS 
Our study shares several limitations. Unfortunately it was not possible to report 
about long-term follow-up or hard clinical events in this population. Moreover we do not 
have detailed data about HAART regimen and almost all patients are male making it 
impossible to appraise specific differences. Third, we reported incidence of coronary 
stenosis more than 30% considering our aim to focus on plaques’ features 
independentely from the percentage of stenosis. Finally, the potential benefit by CCT 
needs to be weighted against its safety related to radiation exposure in asymptomatic 
young patients. Moreover as demonstrated in Table B, most of the included studies were 
of high quality, with an accurate definition of control population. 
 
CONCLUSION 
In this comprehensive meta-analysis, NCP was more prevalent and extensive in 
asymptomatic HIV-infected patients, especially in presence of lower CD4 cell counts. This 
finding provides new details on the differences in atherosclerotic process in HIV-
infected patients, stressing the importance of primary prevention in this population. 
On the other hand the use of CCT may be considered in the future, if supported by 
larger  prospective studies, as a complementary tool to evaluate high risk patients, 
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